From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

Market Update

Julia Lee
September 21, 2018

Equity Investor 17 September

Julia Lee
September 18, 2018

Equity Investor 10 September

Julia Lee
September 11, 2018

Equity Investor 3 September

Julia Lee
September 4, 2018

Market Update

Julia Lee
August 31, 2018

Equity Investor 27 August

Julia Lee
August 28, 2018

Market Update

Julia Lee
August 27, 2018

Market Update

Julia Lee
August 24, 2018

Weekly Wrap 24 August

Julia Lee
August 24, 2018

Market Update 23 August

Julia Lee
August 23, 2018

Weekly Wrap 17 August

Julia Lee
August 17, 2018

Equity Investor 13 August

Julia Lee
August 14, 2018